title: Rebuttal of the Con View: Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD.
abstract: Our opponents in this debate state that there are insufficient data to consider albuminuria as a valid target for therapy in patients with CKD. They base their opinion predominantly on two arguments: first, a decrease in albuminuria is not always associated with renoprotection, and second, no prospective randomized controlled trial has been conducted that really targeted albuminuria.
authors.affiliation: Departments of Clinical Pharmacology and H.J.Lambers.Heerspink@med.umcg.nl.
authors.forename: Hiddo J
authors.initials: HJ
authors.lastname: Lambers Heerspink
authors.affiliation: Nephrology, University Medical Center Groningen, Groningen, The Netherlands.
authors.forename: Ron T
authors.initials: RT
authors.lastname: Gansevoort
mesh_terms: D000419:Albuminuria / Q000628:therapy*; D006801:Humans; D007668:Kidney / Q000187:drug effects*; D051436:Renal Insufficiency, Chronic / Q000628:therapy*; D012709:Serum Albumin / Q000378:metabolism*; D064804:Urological Agents / Q000627:therapeutic use*
chemical_list: D012709:Serum Albumin; D064804:Urological Agents
keywords: CKD; albuminuria; renoprotection